Holen Sie sich die Stockscreener-App
1.0406
3.67%
-0.0494
Handel nachbörslich:
1.05
0.0094
+0.90%
Schlusskurs vom Vortag:
$1.09
Offen:
$1.05
24-Stunden-Volumen:
925.09K
Relative Volume:
4.21
Marktkapitalisierung:
$49.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.39M
KGV:
-1.2388
EPS:
-0.84
Netto-Cashflow:
$-18.45M
1W Leistung:
-7.08%
1M Leistung:
-15.32%
6M Leistung:
-28.08%
1J Leistung:
+9.38%
1-Tages-Spanne:
$1.02
$1.12
1-Wochen-Bereich:
$0.978
$1.18
52-Wochen-Spanne:
$0.5116
$2.45
Quince Therapeutics Inc Stock (QNCX) Company Profile
Firmenname
Quince Therapeutics Inc
Sektor
Branche
Telefon
415-910-5717
Adresse
611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO
Vergleichen Sie QNCX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QNCX
Quince Therapeutics Inc
|
1.0406 | 49.99M | 0 | -31.39M | -18.45M | -0.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.61 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.55 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
615.11 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
269.81 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
241.75 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-24 | Eingeleitet | Oppenheimer | Outperform |
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Why Faraday Future Intelligent Electric Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Quince Therapeutics (QNCX) CEO to Present at Life Sciences Conference - GuruFocus
Geode Capital Management LLC Has $703,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX) - Defense World
Quince Therapeutics to Present at Citizens Life Sciences Conference - BioSpace
Quince Therapeutics Inc (QNCX) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com
Ratios Uncovered: Breaking Down Quince Therapeutics Inc (QNCX)’s Trailing Twelve Months Metrics - DWinneX
Closing Figures Unveiled: Quince Therapeutics Inc (QNCX) Drop -8.93, Closes at 1.02 - DWinneX
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Rating of “Buy” by Analysts - Defense World
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference - BioSpace
Rare Disease Biotech Quince to Unveil Latest Developments at Major Healthcare Conference - Stock Titan
Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday - Defense World
Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
D. Boral Capital Issues Pessimistic Forecast for Quince Therapeutics (NASDAQ:QNCX) Stock Price - The AM Reporter
Analysts Are Bullish on Top Healthcare Stocks: Quince Therapeutics (QNCX), Lucid Diagnostics (LUCD) - The Globe and Mail
Quince Therapeutics (NASDAQ:QNCX) Price Target Lowered to $4.00 at D. Boral Capital - Defense World
Quince Therapeutics Reports 2024 Financial Results and Trial Progress - TipRanks
Quince Therapeutics stock target cut to $4 from $12, maintains buy By Investing.com - Investing.com South Africa
Quince Therapeutics stock target cut to $4 from $12, maintains buy - Investing.com
Quince Therapeutics (NASDAQ:QNCX) Now Covered by Oppenheimer - Defense World
Quince Therapeutics Existing Cash Position To Provide Operating Runway Through Phase 3 Topline Results Into 2026 - MarketScreener
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results - Business Wire
Oppenheimer sets $10 target for Quince Therapeutics stock By Investing.com - Investing.com South Africa
Oppenheimer Initiates Coverage of Quince Therapeutics (QNCX) with Outperform Recommendation - Nasdaq
Oppenheimer Initiates Quince Therapeutics at Outperform -March 24, 2025 at 07:46 am EDT - Marketscreener.com
Oppenheimer sets $10 target for Quince Therapeutics stock - Investing.com
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of “Buy” by Analysts - The AM Reporter
Quince Therapeutics (QNCX) Projected to Post Earnings on Monday - Defense World
Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50 - Defense World
Quince Therapeutics (NASDAQ:QNCX) versus IN8bio (NASDAQ:INAB) Critical Contrast - Defense World
Market Momentum Report: Quince Therapeutics Inc (QNCX)’s Negative Close at 1.41 - The Dwinnex
Pliant, Acelyrin resort to ‘poison pills’ as threat of Concentra buyout looms - Fierce Biotech
Vaxart (NASDAQ:VXRT) vs. Quince Therapeutics (NASDAQ:QNCX) Critical Comparison - Armenian Reporter
Ataxia Treatment Market Size in the 7MM is expected to grow - openPR
Financial Survey: Quince Therapeutics (NASDAQ:QNCX) & Vaxart (NASDAQ:VXRT) - Defense World
Head to Head Comparison: Quince Therapeutics (NASDAQ:QNCX) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Spotlight On Fractyl Health And Two Other Intriguing Penny Stocks - Simply Wall St
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $9.50 Average Price Target from Analysts - Defense World
Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
D. Boral Capital Reiterates "Buy" Rating for Quince Therapeutics (NASDAQ:QNCX) - MarketBeat
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia - Business Wire
Quince Therapeutics secures USPTO nod for A-T treatment patent - MSN
D. Boral Capital Reaffirms “Buy” Rating for Quince Therapeutics (NASDAQ:QNCX) - Defense World
Quince's Rare Disease Drug Trial Accelerates: Key FDA Timeline Revealed - Stock Titan
Quince Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com
Rare Disease Pioneer Quince Therapeutics Takes Center Stage at Major Healthcare Conference - Stock Titan
Quince Therapeutics secures USPTO nod for A-T treatment patent By Investing.com - Investing.com Australia
Quince Therapeutics Receives Notice of Allowance Covering Innovative Method of Use for Lead Indication Ataxia-Telangiectasia - Business Wire
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Earnings Coming in Better-Than-Expected As Peak Season Begins - The Globe and Mail
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Finanzdaten der Quince Therapeutics Inc-Aktie (QNCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quince Therapeutics Inc-Aktie (QNCX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Thye Dirk | CEO AND CHIEF MEDICAL OFFICER |
Aug 29 '24 |
Buy |
0.69 |
77,500 |
53,475 |
766,941 |
| Ryan Charles S. | PRESIDENT |
Aug 20 '24 |
Buy |
0.65 |
48,387 |
31,452 |
122,461 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 21 '24 |
Buy |
0.63 |
30,845 |
19,337 |
296,540 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 20 '24 |
Buy |
0.60 |
5,924 |
3,579 |
265,695 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Aug 19 '24 |
Buy |
0.58 |
2,155 |
1,250 |
259,771 |
| Hannah Brendan | CHIEF BUSINESS OFFICER AND COO |
Jun 04 '24 |
Option Exercise |
0.55 |
56,061 |
30,834 |
257,616 |
6.54%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):